← Leaderboards
Hugo W Moser
Johns Hopkins University
$5,176,943
Attributed
$5,176,943
Total exposure
23
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$8,117,160 · 23
FDA$348,098 · 1
By mechanism
R01$3,878,398 · 2
P01$3,790,506 · 2
N01$445,878 · 1
P41$208,516 · 5
M01$141,960 · 14
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Gerald V Raymond$6,168,992
- Tza-Huei Jeff Wang$29,391,444
- Luke C Mullany$3,103,711
- Michal L Melamed$11,008,976
- Todd T Brown$33,742,320
Others in their field
Top investigators on “Adrenoleukodystrophy”
- John S. Lollar · Emory University$12,135,598
- Gerald V Raymond · Johns Hopkins University$6,168,992
- Inderjit Singh · Medical University Of South Carolina$5,834,604
- Jaspreet Singh · Henry Ford Health System$3,415,536
- Patricia L Musolino · Massachusetts General Hospital$3,009,180
- Steven Upshaw Walkley · Yeshiva University$3,006,000
Research focus
AdrenoleukodystrophyClinical ResearchHuman SubjectHuman Therapy EvaluationPeroxisomePhenotypeMagnetic Resonance ImagingMolecular PathologyGenetic DisorderPathologic ProcessLongitudinal Human StudyLong Chain Fatty AcidMental RetardationNeuropsychological TestsSex Linked TraitDiet TherapyChild (0-11)GenotypePatient Oriented ResearchNutrition Related TagOral AdministrationClinical TrialsNeuroimagingDrug Screening /Evaluation
Grant awards (51)
X-LINKED ADRENOLEUKODYSTROPHY$31,771
P41 · FY2010 · RR · contact PI
X-LINKED ADRENOLEUKODYSTROPHY$32,050
P41 · FY2009 · RR · contact PI
X-LINKED ADRENOLEUKODYSTROPHY$22,050
P41 · FY2008 · RR · contact PI
X-LINKED ADRENOLEUKODYSTROPHY$34,526
P41 · FY2007 · RR · contact PI
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY$3,489
M01 · FY2007 · RR · contact PI
THERAPEUTIC TRIALS OF X-LINKED ALD: PHASE III; LORENZO*$348,098
R01 · FY2006 · FD · contact PI
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY$37,441
P41 · FY2006 · RR · contact PI
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY$19,728
M01 · FY2006 · RR · contact PI
EFFECT OF GLYCEROL TRIERUCATE ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY$14,796
M01 · FY2006 · RR · contact PI
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY$2,466
M01 · FY2006 · RR · contact PI
EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD$411
M01 · FY2006 · RR · contact PI
Multicenter Therapeutic Trials of X-Linked ALD$800,000
R01 · FY2005 · HD
Multicenter Therapeutic Trails of X-Linked ALD Supplement$570,300
R01 · FY2005 · HD
EFFECT OF GLYCEROL TRIERUCATE ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY$29,158
M01 · FY2005 · RR
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY$25,915
P41 · FY2005 · RR
STUDIES IN ADRENOMYELONEUROPATHY$11,713
M01 · FY2005 · RR
STUDIES IN ADRENOMYELONEUROPATHY$8,224
M01 · FY2005 · RR
EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD$1,495
M01 · FY2005 · RR
Multicenter Therapeutic Trials of X-Linked ALD$800,000
R01 · FY2004 · HD
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY$24,763
P41 · FY2004 · RR
Studies in Adrenomyeloneuropathy$18,176
M01 · FY2004 · RR
Studies in Adrenomyeloneuropathy$16,139
M01 · FY2004 · RR
Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy$13,788
M01 · FY2004 · RR
Effect of Glyceryl Trierucate Therapy of ALD$2,037
M01 · FY2004 · RR
Effect of Docosahexaenoic Acid Therapy in Peroxisomal Disorders$340
M01 · FY2004 · RR
Multicenter Therapeutic Trials of X-Linked ALD$720,000
R01 · FY2003 · HD
Multicenter Therapeutic Trials of X-Linked ALD$640,000
R01 · FY2002 · HD
DOCOSAHEXAENOIC ACID THERAPY IN PEROXISOMAL DISORDERS$0
M01 · FY2002 · RR
PHENYLBUTYRATE THERAPY FOR ADRENOLEUKODYSTROPHY$0
M01 · FY2002 · RR
PEROXISOMAL DISORDERS--GENOTYPE, PHENOTYPE, PATHOGENESIS AND THERAPY$0
M01 · FY2002 · RR
EFFECT OF GLYCERYL TRIERUCATE THERAPY ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY$0
M01 · FY2002 · RR
GENETIC CAUSES OF MENTAL RETARDATION$1,647,572
P01 · FY2001 · HD
PHENOTYPE GENOTYPE CORRELATIONS IN PEROXISOMAL DISORDERS$176,978
P01 · FY2001 · HD
PEROXISOMAL DISORDERS--GENOTYPE, PHENOTYPE, PATHOGENESIS AND THERAPY$0
M01 · FY2001 · RR
PHENYLBUTYRATE THERAPY FOR ADRENOLEUKODYSTROPHY$0
M01 · FY2001 · RR
DOCOSAHEXAENOIC ACID THERAPY IN PEROXISOMAL DISORDERS$0
M01 · FY2001 · RR
EFFECT OF GLYCERYL TRIERUCATE THERAPY ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY$0
M01 · FY2001 · RR
GENETIC CAUSES OF MENTAL RETARDATION$1,317,520
P01 · FY2000 · HD
BIOMEDICAL APPLICATIONS OF THE NEXT GENERATION INTERNET$445,878
N01 · FY2000 · LM
PHENOTYPE GENOTYPE CORRELATIONS IN PEROXISOMAL DISORDERS$325,213
P01 · FY2000 · HD
GENETIC CAUSES OF MENTAL RETARDATION$269,901
P01 · FY2000 · HD
GENETIC CAUSES OF MENTAL RETARDATION$33,322
P01 · FY2000 · HD
GENETIC CAUSES OF MENTAL RETARDATION$20,000
P01 · FY2000 · HD
EFFECT OF GLYCERYL TRIERUCATE THERAPY ON CLINICAL COURSE OF ADRENOLEUKODYSTROPHY$0
M01 · FY2000 · RR
PHENOTYPE GENOTYPE CORRELATIONS IN PEROXISOMAL DISORDERS$0
P01 · FY2000 · HD
PHENOTYPE GENOTYPE CORRELATIONS IN PEROXISOMAL DISORDERS$0
P01 · FY2000 · HD
PHENOTYPE GENOTYPE CORRELATIONS IN PEROXISOMAL DISORDERS$0
P01 · FY2000 · HD
BIOMEDICAL APPLICATIONS OF THE NEXT GENERATION INTERNET$0
N01 · FY2000 · LM
DOCOSAHEXAENOIC ACID THERAPY IN PEROXISOMAL DISORDERS$0
M01 · FY2000 · RR
PEROXISOMAL DISORDERS--GENOTYPE, PHENOTYPE, PATHOGENESIS AND THERAPY$0
M01 · FY2000 · RR
PHENYLBUTYRATE THERAPY FOR ADRENOLEUKODYSTROPHY$0
M01 · FY2000 · RR